Topic Hub
6 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 6 of 6 clinical reviews.
A critical appraisal of the HORIZON-PFT trial examining enrollment biases, generalizability gaps, statistical caveats, conflict-of-interest disclosures, and what post-publication commentary revealed about yearly IV zoledronic acid for osteoporosis.
Read clinical reviewHealth-economic analysis of the HORIZON-PFT trial: cost per QALY for yearly IV zoledronic acid, payer coverage patterns, list vs net pricing, and patient-level value calculations.
Read clinical reviewDeep dive into the HORIZON-PFT extension study: how zoledronic acid's fracture protection held up beyond 3 years, what safety signals emerged, and clinical implications for long-term bisphosphonate therapy.
Read clinical reviewComplete breakdown of HORIZON-PFT trial outcomes for zoledronic acid IV: primary and secondary endpoint effect sizes, confidence intervals, time-course data, and subgroup analyses from the landmark 2007 NEJM publication.
Read clinical reviewA detailed methodological dissection of the HORIZON-PFT trial examining how zoledronic acid's 70% vertebral fracture reduction was designed, measured, and should be interpreted.
Read clinical reviewA deep-dive into the HORIZON-PFT trial of yearly IV zoledronic acid for osteoporosis, examining how its results reshaped guidelines, prescribing patterns, and patient selection beyond the abstract.
Read clinical review